Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review.
Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review.
复制标题
Liraglutide在现实世界中2型糖尿病治疗中的临床有效性：系统文献综述。
DOI：
10.1007/s13300-016-0180-0
复制
发表时间：
2016-09
期刊：
影响因子：
--
通讯作者：
Xu W
中科院分区：
文献类型：
--
作者：
Ostawal A;Mocevic E;Kragh N;Xu W
在临床试验中，利拉鲁肽已被证明是治疗2型糖尿病(T2 DM)的有效药物。利拉鲁肽在现实世界中的有效性已经在许多研究中进行了调查。本系统文献综述的目的是整理有关利拉鲁肽临床疗效的证据。对Medline、EMBASE、Cochrane图书馆的出版物和会议记录进行了审查，以确定评估利拉鲁肽在现实世界临床实践中的临床有效性的观察性研究。这项审查是根据国家健康与护理卓越研究所(NICE)的指导进行的。除会议议事程序(2013-2015)外，没有适用任何语文或时间限制。数据提取的端点是先验确定的。对全文期刊论文进行研究质量评价。在纳入综述的124种出版物中，有43篇是全文文章。利拉鲁肽在开始治疗的6个月内显著降低糖化血红蛋白(HbA1c)(HbA1c从基线的平均变化：−0.9%至−2.2%；HbA1c<；7.0%：29.5%-65.0%)。接受利拉鲁肽治疗的患者中有16.9-47.0%的患者达到了NICE复合终点(糖化血红蛋白降低≥1%，体重减轻≥3%)。利拉鲁肽治疗导致绝对体重平均改变，从基线的−1.3g降至−8.65g。利拉鲁肽治疗2型糖尿病患者耐受性良好。利拉鲁肽单药治疗的低血糖发生率为≤0.8%。低血糖在服用降糖药物(0.0%-15.2%)和利拉鲁肽的患者中更为常见。利拉鲁肽治疗T2 DM患者的有益血糖和体重效应至少维持了12个月。来自反映现实世界临床实践的观察性研究的证据表明，利拉鲁肽疗法改善了血糖控制，降低了低血糖风险，并与T2 DM患者的显著体重减轻有关。这些观察结果与临床试验结果一致。诺和诺德A/S，S，丹麦。本文的在线版本(doi：10.1007/s13300-0160180-0)包含补充材料，授权用户可以使用。
In clinical trials, liraglutide has proven to be an effective drug for the treatment of type 2 diabetes mellitus (T2DM). The real-world effectiveness of liraglutide has been investigated in numerous studies. The aim of this systematic literature review is to collate evidence on the real-world clinical effectiveness of liraglutide. A review of publications from Medline, EMBASE, the Cochrane Library, and conference proceedings was conducted to identify observational studies that assessed the clinical effectiveness of liraglutide in real-world clinical practice. This review was conducted according to the National Institute of Health and Care Excellence (NICE) guidance. No language or time limits were applied, except to the conference proceedings (2013–2015). Endpoints for data extraction were decided a priori. Study quality appraisal was done for full-text journal articles. Of 124 publications included in the review, 43 were full-text articles. Liraglutide significantly reduces glycated hemoglobin (HbA1c) within 6 months of initiating treatment (mean change in HbA1c from baseline: −0.9% to −2.2%; HbA1c <7.0%: 29.5–65.0%). The NICE composite endpoint (HbA1c reduction ≥1% and weight reduction ≥3%) was met in 16.9–47.0% of patients with liraglutide treatment. Liraglutide therapy led to a mean change in absolute weight from baseline of −1.3 to −8.65 kg. Liraglutide treatment was well tolerated in patients with T2DM. The rate of occurrence of hypoglycemia with liraglutide monotherapy was ≤0.8%. Hypoglycemia was more common in patients taking antidiabetic medications (0.0–15.2%) together with liraglutide. The beneficial glycemic and weight effect of liraglutide therapy in patients with T2DM was maintained for at least 12 months. Evidence from observational studies reflecting real-world clinical practice demonstrates that liraglutide therapy improves glycemic control with a low risk of hypoglycemia, and is associated with significant weight loss in patients with T2DM. These observations are consistent with clinical trial findings. Novo Nordisk A/S, Søborg, Denmark. The online version of this article (doi:10.1007/s13300-016-0180-0) contains supplementary material, which is available to authorized users.